Introduction
Allogeneic bone marrow transplantation (BMT) is a widely performed therapy for many hematologic malignancies. Effective use of this powerful therapeutic modality has been hindered by its significant toxicity, acute graft-versus-host disease (GVHD). However, the graft-versus-leukemia (GVL) effect provided by allogeneic BMT represents a very potent form of immune therapy against malignancy. 1 Unfortunately, GVHD and GVL are tightly linked as demonstrated by the inverse correlation between leukemia relapse rates and the severity of GVHD. [2] [3] [4] Prevention of GVHD by T-cell depletion or nonspecific immune suppression is associated with increased risk for leukemia relapse after allogeneic BMT. [5] [6] [7] Thus, approaches that can reduce the toxicity of GVHD while preserving the beneficial GVL effects are necessary to better harness this very effective therapeutic modality against hematologic malignancies.
Interleukin 18 (IL-18) is a recently discovered cytokine that is structurally related to IL-1 but functionally similar to IL-12. 8 It is produced by a wide variety of cells such as macrophages, dendritic cells, keratinocytes, T cells, osteoblasts, and Kupffer cells and is a potent inducer of Th1 response in concert with IL-12. 8, 9 We have recently demonstrated that when administered early after allogeneic BMT it can significantly attenuate acute GVHD. 10 Because IL-18 enhances the cytolytic activity of T cells and has been shown to provide antitumor immunity, 8, 11, 12 we examined whether IL-18 could preserve the GVL effect conferred by donor T cells after allogeneic BMT.
Study design Mice
and perforin-deficient C57BL/6 (H-2 b , pfp Ϫ/Ϫ ) mice were purchased from the Jackson Laboratory (Bar Harbor, ME). Mice were housed and fed as previously described. 10 All the methods were done as described previously. 10, [13] [14] [15] [16] 
Bone marrow transplantation
Mice underwent transplantation according to a standard protocol described previously. 13 Briefly, on day 0 mice received 13 Gy total body irradiation (TBI; 137 Cs source) split into 2 doses. After TBI, 5 ϫ 10 6 T-cell-depleted (TCD) bone marrow (BM) and 2 ϫ 10 6 nylon wool purified (NWP) splenic donor T cells were injected intravenously into recipients. Survival was monitored daily; recipient body weight and GVHD clinical score were measured weekly. 10, 13 
IL-18 treatment
Recombinant murine IL-18 (RD, Flanders, NJ) was reconstituted per the manufacturer's recommendations in sterile distilled H 2 O and injected intraperitoneally (10 g/mouse/d) from day Ϫ2 to ϩ2. Mice from the control groups received phosphate-buffered saline (PBS).
Leukemia induction
Briefly, 2000 P815 (H-2 d ) cells (a mastocytoma derived from a DBA/2 mouse) were injected intravenously into B6D2F1 recipients on day 0 along with the BM transplant inoculum. Survival was monitored daily. P815-induced leukemic death was defined by the occurrence of either macroscopic tumor nodules in liver or spleen or hindleg paralysis. 15 GVHD death was defined by the absence of leukemia and the presence of clinical signs of GVHD. 13, 14 Animals surviving beyond day 50 after BMT were killed and the liver and spleen were harvested for flow cytometric evaluation (has sensitivity of 0.5% 15 ).
Fluorescence-activated cell sorting analysis
Fluorescein isothiocyanate-conjugated monoclonal antibodies to mouse CD45.1 ϩ , CD45.2 ϩ , and H-2 dϩ , phycoerythrin-conjugated CD4 ϩ , CD8 ϩ , and H-2 bϩ were purchased from Pharmingen (San Diego, CA). Cells were analyzed by 2-color flow cytometry on a FACScan cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA). 13, 15 
Cell cultures
Briefly, splenocytes were harvested from animals 14 days after transplantation and 3 spleens combined from each group. Donor (CD45.1 ϩ CD3 ϩ ) T cells in the spleens were determined and normalized between groups. Donor T-cell engraftment was 94% Ϯ 4% in the controls and 86% Ϯ 8% in IL-18 recipients (P ϭ NS) on day ϩ14 after BMT. These cells were then plated in 96-well flat-bottomed plates (Falcon, Lincoln Park, NJ) at a concentration of 2 ϫ 10 5 T cells (CD45.1 ϩ CD3 ϩ )/well with 2 ϫ 10 5 irradiated (2000 rad) splenocytes harvested from naive B6D2F1 (allogeneic) or B6 (syngeneic) animals. At 48 hours, supernatants were collected for cytokine analysis and the cultures were pulsed with 3 [H]-thymidine (1 Ci/well; 0.037 MBq) and proliferation was determined 24 hours later on a 1205 Betaplate reader (Packard, Downers Grove, IL).
Cytokine ELISAs
Antibodies used in the interferon ␥ (IFN-␥) and IL-2 assays were purchased from Pharmingen. All assays were performed according to the manufacturer's protocol in a 1:5 dilution. Plates were read at 450 nm using a microplate reader (Bio-Rad Labs, Hercules, CA). Recombinant murine IFN-␥ and IL-2 (Pharmingen) were used as standards for enzyme-linked immunosorbent assays (ELISAs). Samples and standards were run in duplicate and the sensitivity of the assays was 0.063 U/mL for IFN, and less than 0.13 U/mL for IL-2.
Cr release assays
Briefly, splenocytes were removed from B6D2F1 recipients 14 days after BMT, and 3 spleens were combined from each group. Donor CD8 ϩ cells in each group were determined and the counts were normalized. They were added at varying effector to target ratios and incubated for 4 hours with either allogeneic P815 (H-2 d ) or syngeneic EL-4 (H-2 b ) targets (2 ϫ 10 6 cells), labeled with 100 Ci (3.7 MBq) 51 Cr. 51 Cr activity in supernatants was determined in an autogamma counter (Packard Instrument, Meriden, CT). The percentage of specific lysis was calculated as follows: 100 ϫ (sample count Ϫ background count)/(maximal count Ϫ background count). 15 
Statistical analysis
Survival curves were plotted using Kaplan-Meier estimates. The MantelCox log-rank test was used to analyze survival data. Statistical significance was set at P Ͻ .05.
Results and discussion
We have previously demonstrated that administration of IL-18 early in the time course of allogeneic BMT attenuated early in vivo donor T-cell proliferation by enhancing activation induced Fas-mediated apoptosis and resulted in reduced GVHD. 10 We now determined whether the effects of IL-18 on acute GVHD severity were also associated with a decrease in donor responses to host antigens after BMT. B6D2F1 mice received 13 Gy of TBI followed by infusion of BM and T cells from either allogeneic B6 Ly5.2 or syngeneic donors as described in "Study design." Donor splenic T cells were harvested from allogeneic BM transplant recipients on day ϩ14 and then restimulated in vitro with B6D2F1 stimulators in standard mixed lymphocyte reaction (MLR) cultures. As shown in Figure 1A , splenic T cells from both IL-18-treated or control allogeneic recipients displayed similar proliferative responses to host antigens. There was also no difference in secretion of either IFN-␥ or IL-2 between T cells from IL-18-treated or control mice ( Figure 1B,C) . We next tested the cytotoxic capability of donor CD8 ϩ T cells harvested from recipient spleens on day ϩ14 against host type P815 (H2 d ) tumor targets, which was also equivalent between the 2 groups ( Figure 1D ). Taken together with our previous study, 10 these data demonstrate that administration of IL-18 to BM transplant recipients attenuates donor T-cell proliferation by enhancing Fas-mediated increasing activation induced cell death early after BMT but does not alter donor T-cell responses to host antigens measured 2 weeks after BMT.
The preservation host-specific responses in donor cells suggested that GVL effects might be preserved. We next determined the ability of IL-18 treatment to promote leukemia-free survival after allogeneic BMT in a well-established mouse GVL model described in "Study design." 15, 16 As expected all recipients of syngeneic BM transplants receiving P815 tumor cells died with evidence of massive hepatosplenomegaly. Although IL-18 by itself has been shown to possess antitumor effects, 8, 17 all IL-18-treated syngeneic mice that received P815 cells also died from leukemia by day 18, thus ruling out any direct antitumor effect of IL-18 in this system ( Figure 2A ). All allogeneic BM transplant recipients treated with control died by day 40. By contrast, 50% of IL-18-treated allogeneic animals survived the entire observation period (P Ͻ .03). Clinical GVHD scores were also more severe in controls than in IL-18-treated animals (5.6 Ϯ 0.7 versus 3.5 Ϯ 0.4, P Ͻ .05) consistent with our previous observation. 10 In each case, allogeneic recipients effectively rejected their leukemia with no evidence of tumor at autopsy. In additional experiments with a lower dose (1 ϫ 10 6 ) of allogeneic T cells, 25% of the control compared to 70% of IL-18-treated recipients survived (P Ͻ .04) and had less clinical GVHD. No animals showed morphologic evidence of leukemia at the end of the observation period, demonstrating that IL-18 preserved GVL effect at both higher and lower T-cell doses. We tested for minimal residual leukemia by killing all the surviving animals on day 50 and analyzing peripheral blood and splenocytes Figure 1 . Donor T-cell cytokine and cytolytic functions after BMT. B6D2F1 animals were injected with control diluent (solid bar) or IL-18 (dotted bar) from day Ϫ2 to ϩ2, received 13 Gy TBI, and received transplants of 5 ϫ 10 6 TCD BM and 2 ϫ 10 6 splenic T cells from B6 Ly5.2 (CD45.1 ϩ ) donor mice. Splenocytes from the recipients (n ϭ 3/group) were harvested on day 14 after BMT, combined and normalized for donor T cells (CD45.1 ϩ and CD3 ϩ ); and restimulated in quadruplicate with irradiated naive host (B6D2F1) splenocytes in MLR cultures. Supernatants were collected after 48 hours of culture and proliferation was determined by pulsing with [ 3 H]-thymidine (1 Ci/well; 0.037 MBq) for an additional 20 hours. T-cell proliferation (A), IFN-␥ secretion (B), and IL-2 production (C) were all similar (solid bar versus dotted bar, P ϭ NS). Results from 1 of 3 similar experiments are shown. (D) Splenocytes harvested from allogeneic animals on day 14 after BMT were pooled (n ϭ 3/group), and normalized for donor CD8 ϩ cells and used in a 51 Cr release assay. CTL activity against allogeneic P815 in control (OE) and IL-18 (F) groups was similar; there was no significant lysis of syngeneic targets by either group (IL-18, Ⅺ; control, f) . Earlier studies have demonstrated that CD8 ϩ T cells are more potent effectors of GVL than are CD4 ϩ cells in several models. 15, 18, 19 CD8 ϩ cells mediate cytotoxicity, which is critical for GVL effect, either by the perforin-granzyme granule exocytosis pathway or the Fas pathway. 20 Several recent studies have demonstrated that perforin rather than Fas ligand (FasL) is important for GVL activity. [19] [20] [21] We therefore evaluated the cytotoxic mechanisms responsible for GVL by using perforin (pfp)-deficient B6 (H2 b ) mice as donors and undergoing transplantation as above. Consistent with previous studies, most of the recipients of allogeneic perforin-deficient splenic T cells treated with control diluent died from GVHD ( Figure 2B) . 22, 23 In contrast, IL-18 treatment conferred a significant survival advantage to allogeneic BM transplant recipients (88% versus 12%; Figure 2B ). When F1 recipients were injected with P815 at the time of BMT all the recipients died from leukemia regardless of treatment if they received perforin-deficient donor T cells ( Figure 2C ). These data indicate that the perforin-dependent cytotoxicity of donors is critical for preservation of GVL activity in this model.
Interleukin 18 did not impede engraftment of donor marrow in this parent into F1 model. 10 It should be noted, however, that the effects of IL-18 in other models where rejection might be mediated by T cells as well as natural killer cells have not yet been evaluated. Immune reconstitution after IL-18 treatment was also better than controls in this model (data not shown) and IL-18 has been shown to be critical for defense against cytomegalovirus 24, 25 and Aspergillus. 26, 27 Thus IL-18 treatment may reduce the risk of opportunistic infections after allogeneic BMT, but detailed evaluation of this effect of IL-18 on posttransplantation immune responses against infections remains to be determined.
In conclusion, when taken together with our previous study, 10 these data demonstrate that brief administration of IL-18 to recipients early after allogeneic BMT may represent a novel strategy to attenuate acute GVHD without compromising GVL activity. All syngeneic (f, n ϭ 10), allogeneic control (F, n ϭ 10), allogeneic IL-18-treated pfp Ϫ/Ϫ T cells (E, n ϭ 10) and allogeneic IL-18-treated wild-type T cells (Ⅺ, n ϭ 10) survived. P ϭ NS, E versus F; and P Ͻ .04, Ⅺ versus E.
